| Short Description : | Recombinant-SARS-CoV-2 Spike S1+S2 ECD (S-ECD)-C-His&Avi protein was developed in hek293 cells using the region NA. For use in research applications. |
| Host: | HEK293 cells |
| Note: | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Conjugation: | Unconjugated |
| Formulation: | Lyophilised from a 0.22 Mu m filtered solution of PBS, pH 7.4 or Supplied as a 0.22 Mu m filtered solution in PBS, pH 7.4.Contact us for customized product form or formulation. |
| Storage Instruction: | Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Determination Method: | < 1 EU/Mu g of the protein by LAL method. |
| Immunogen: | Recombinant SARS-CoV-2 (2019-nCoV) S1+S2 ECD ( S-ECD ) Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence Val16-Glu1188 of SARS-COV-2 (2019-nCoV) S1+S2 ECD ( S-ECD ) (Accession #QHD43416.1) fused with |
| Immunogen Sequence: | CVNLTTRTQLPPAYTNSFTR GVYYPDKVFRSSVLHSTQDL FLPFFSNVTWFHAIHVSGTN GTKRFDNPVLPFNDGVYFAS TEKSNIIRGWIFGTTLDSKT QSLLIVNNATNVVIKVCEFQ FCNDPFLGVYYHKNNKSWME SEFRVYSSANNCTFEYVSQP FLMDLEGKQGNFKNLREFVF KNIDGYFKIYSKHTPINLVR DLPQGFSALEPLVDLPIGIN ITRFQTLLALHRSYLTPGD |
